Genmab — September 2017
-
meanwhile, NICE is not just difficult with Dara ; NICE throws a wrench in Takeda's Ninlaro growth plans with second rejection http://www.fiercepharma.com/pharma/nice-burns-takeda-again-second-ninlaro-rejection
-
CAR-T tourism starting? "... According to a Chinese media report this week, an American patient paid out of his own pocket to go to China to access what is perhaps the most promising technology .." https://www.myeloma.org/blog/dr-duries/university-california-girds-combat-cancer-closer-look-car-t-cell-therapy-and-medical?utm_content=buffer10ca4&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
-
-
det Jan sagde var at sidste uge i august var bedste uge overhovedet. Det er selvfølgelig godt, men man burde jo håbe at august som sådan var bedste måned, men det sagde han ikke. August skal i hvertfald være markant bedre end juli ellers har vi problemer.
-
Darzalex er og bliver markant bedre end alt andet, derfor skal patienter have muligheden for Dara før alt andet og næste skridt må blive om Dara skal puttes i vitaminpiller, mere er der ikke at sige til det. Salget giver sig selv efterhånden som folk får lange responser og kroniske "tilstande", sådan som forskningen tilskriver det. Risikoen er stort set 0 og skal eller rettere burde indregnes fuldt ud i
kursen.
️
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind